Table 1.
Baseline patients’ characteristics.
| Overall (n = 101) | UC (n = 59) | CD (n = 42) | p | |
|---|---|---|---|---|
| Female – n (%) | 38 (37.6) | 20 (33.9) | 18 (42.9) | 0.36 |
| Mean age – years (IQR) | 47.9 (45–50.8) | 47.4 (43.5–51.2) | 48.7 (44–53.4) | 0.65 |
| Smokers – n (%) | 13 (13) | 5 (8.5) | 8 (19) | 0.12 |
| Montreal – n (%) | ||||
| A1 | 2 (4.7) | |||
| A2 | 27 (64.3) | |||
| A3 | 13 (31) | |||
| L1 | 13 (30.9) | |||
| L2 | 6 (14.3) | |||
| L3 | 22 (52.4) | |||
| L4 | 1 (2.3) | |||
| B1 | 23 (54.8) | |||
| B2 | 13 (30.9) | |||
| B3 | 6 (14.3) | |||
| P | 6 (14.3) | |||
| E1 | 1 (1.7) | |||
| E2 | 20 (33.9) | |||
| E3 | 38 (64.4) | |||
| Previous surgery – n (%) | 27 (26.7) | 0 | 27 (64.3) | |
| Previous exposure to anti-TNFα – n (%) | 83 (82.2) | 48 (81.4) | 35 (83.3) | 0.8 |
| 1 – n (%) | 39 (38.6) | 27 (45.8) | 12 (28.6) | 0.08 |
| 2 – n (%) | 40 (39.6) | 18 (30.5) | 22 (52.4) | 0.02 |
| 3 – n (%) | 4 (4) | 3 (5.1) | 1 (2.3) | 0.49 |
| Concomitant immunosuppressants-n (%) | 8 (7.9) | 5 (8.5) | 3 (7.1) | 0.8 |
| Steroid use at baseline | 50 (49.5) | 38 (64) | 12 (28.5) | 0.0005 |
| Median BMI – (IQR) | 22.9 (20.9–24.8) | 23.6 (21.1–25.7) | 22.8 (16.8–24.1) | 0.53 |
| Median CRP – mg/l (IQR) | 8 (2.1–13.4) | 5.4 (1–12.8) | 9.4 (4–14) | 0.34 |
| Median serum albumin – g/l (IQR) | 3.8 (3.5–4.2) | 3.9 (3.5–4.2) | 3.7 (3.5–4.1) | 0.8 |
| Median PMS, (IQR) | – | 6 (6–7) | – | |
| Median HBI, (IQR) | – | – | 8 (8–10) | |
anti-TNFα: anti-tumour necrosis factor alpha; BMI: body mass index; CD: Crohn's disease; CRP: C-reactive protein; HBI: Harvey Bradshaw Index; IQR: interquartile range; PMS: Partial Mayo score; UC: ulcerative colitis.